Ipsens Onivyde Pancreatic Cancer Trial Survival Disappointment Dashes Sales Boost Hopes
Merely Matches FOLFIRINOX OS
The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.
You may also be interested in...
The French firm’s Onivyde has missed the mark in an advanced small-cell lung cancer Phase III trial, prompting the firm to tout the drug’s prospects in a large pancreatic cancer indication instead.
After CEO David Loew declared again that Ipsen would be very active in the dealmaking space, Ipsen is paying $45m upfront to access two immuno-oncology candidates from Marengo and bagged an ERK inhibitor from AGV Discovery.
Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.